| An Online Decision Aid for Patients With Metastatic Melanoma—Results of the Randomized Controlled Trial" PEF-Immun". P Grabbe, MS Borchers, KM Gschwendtner, S Strobel, B Wild, M Kirchner, ... Deutsches Arzteblatt International, arztebl. m2024. 053-arztebl. m2024. 053, 2024 | | 2024 |
| Chemokines and Cytokines in Immunotherapy of Melanoma and Other Tumors: From Biomarkers to Therapeutic Targets R Reschke, AH Enk, JC Hassel International Journal of Molecular Sciences 25 (12), 6532, 2024 | | 2024 |
| Phase 3 study (PIVOTAL) of neoadjuvant intralesional daromun vs. immediate surgery in fully resectable melanoma with regional skin and/or nodal metastases. A Hauschild, JC Hassel, M Ziemer, P Rutkowski, FE Meier, L Flatz, ... Journal of Clinical Oncology 42 (17_suppl), LBA9501-LBA9501, 2024 | | 2024 |
| Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse events EAT Koch, A Petzold, E Dippel, M Erdmann, A Gesierich, R Gutzmer, ... Frontiers in Immunology 15, 1395225, 2024 | | 2024 |
| Side effects of oncologic therapies L Zimmer, JC Hassel Dermatologie (Heidelberg, Germany) 75 (6), 437-439, 2024 | | 2024 |
| Nebenwirkungen onkologischer Therapien L Zimmer, JC Hassel Die Dermatologie 75 (6), 437-439, 2024 | | 2024 |
| Safety and efficacy of immune checkpoint inhibitors (ICI) in patients (pts) with pre-existing neurologic autoimmune diseases (NAID) and Parkinson's disease. K Fletcher, A Nassar, AM Menzies, GV Long, F Aboubakar Nana, ... Journal of Clinical Oncology 42 (16_suppl), 2653-2653, 2024 | | 2024 |
| Comparison of clinical outcomes of stable disease with confirmed tumor reduction and RECIST partial response for tebentafusp in metastatic uveal melanoma (mUM). A Ikeguchi, T Sato, MO Butler, RD Carvajal, JJ Sacco, AN Shoushtari, ... Journal of Clinical Oncology 42 (16_suppl), 9529-9529, 2024 | | 2024 |
| Breaking the Mold: Trailblazing Melanoma Therapy Beyond Checkpoint Through Innovative Approaches N Kidwai, M Chen, MA Postow, J Hassel, M Callahan American Society of Clinical Oncology Educational Book 44 (3), e432462, 2024 | | 2024 |
| Checkpoint inhibitor–induced lichen planus differs from spontaneous lichen planus on the clinical, histological, and gene expression level B Meier-Schiesser, C Zecha, S Zierold, I Kolm, M Röckel, W Fröhlich, ... JAAD international 15, 157-164, 2024 | 2 | 2024 |
| Nebenwirkungsmanagement bei Immuncheckpointinhibition P J Bröckelmann, JC Hassel Die Onkologie, 1-8, 2024 | | 2024 |
| Nebenwirkungen dermatoonkologischer Therapien JC Hassel, L Zimmer Die Dermatologie, 1-10, 2024 | | 2024 |
| Side effects of dermato-oncologic therapies JC Hassel, L Zimmer Dermatologie (Heidelberg, Germany), 2024 | | 2024 |
| First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 study SP D’Angelo, C Lebbé, L Mortier, AS Brohl, N Fazio, JJ Grob, N Prinzi, ... ESMO open 9 (5), 103461, 2024 | | 2024 |
| Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors’ perspective KC Kähler, R Gutzmer, Y Angela, E Livingstone, G Lodde, F Meiss, ... Journal of Cancer Research and Clinical Oncology 150 (5), 1-15, 2024 | | 2024 |
| The RANKL inhibitor denosumab in combination with dual checkpoint inhibition is associated with increased CXCL-13 serum concentrations K Schaper-Gerhardt, R Gutzmer, Y Angela, L Zimmer, E Livingstone, ... European Journal of Cancer 202, 113984, 2024 | | 2024 |
| Anti-PD-(L) 1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma LJ Albrecht, F Dimitriou, P Grover, JC Hassel, M Erdmann, A Forschner, ... European Journal of Cancer 202, 113976, 2024 | 2 | 2024 |
| Early serum markers for immune checkpoint inhibitor induced hypophysitis in melanoma patients F Mitri, D Machiraju, C Naoum, JC Hassel Cancers 16 (7), 1340, 2024 | 1 | 2024 |
| Altered serum metabolome as an indicator of paraneoplasia or concomitant cancer in patients with rheumatic disease K Gente, M Feisst, D Marx, KD Klika, P Christopoulos, J Graf, J Will, T Luft, ... Annals of the Rheumatic Diseases, 2024 | | 2024 |
| The role of tissue-resident memory T cells as mediators for response and toxicity in immunotherapy-treated melanoma—two sides of the same coin? R Reschke, B Deitert, AH Enk, JC Hassel Frontiers in Immunology 15, 1385781, 2024 | 1 | 2024 |
